Matribhumi Samachar English
Toronto, Ontario–(Newsfile Corp. – December 11, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo“) a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal …
Read More »Telo Genomics Corp. to File Statement of Defence and Counterclaim to Lawsuit Filed by Former President
Toronto, Ontario–(Newsfile Corp. – June 30, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics“) has received a Statement of Claim filed by Sherif Louis, the former President of the Company, in the amount of approximately $530,000 for notice and bonuses that he claims are …
Read More »European Hematology Association Accepts Abstract from Telo Genomics for Presentation at The 2025 Congress
Toronto, Ontario–(Newsfile Corp. – May 15, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the European Hematology Association (“EHA”) has accepted Telo Genomics’ …
Read More »Telo Genomics Announces Acceptance of its MRD Validation Data in Multiple Myeloma for ASCO 2025
Toronto, Ontario–(Newsfile Corp. – April 10, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted …
Read More »Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors
Toronto, Ontario–(Newsfile Corp. – April 4, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics”) a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company’s …
Read More »Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors
Toronto, Ontario–(Newsfile Corp. – March 12, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics”) a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce Mr. Guido Baechler, has assumed the role …
Read More »Telo Genomics Announces Expanded Partnership with Trusted Health Advisors
Toronto, Ontario–(Newsfile Corp. – February 27, 2025) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics”) announces that, further to its engagement with Trusted Health Advisors (“THA”), as disclosed in a news release dated January 30, 2024, the Company has expanded and extended its agreement (the …
Read More »